Study Finds Triple-Negative Breast Cancer Patients Benefit From Genetic Screening

Study Finds Triple-Negative Breast Cancer Patients Benefit From Genetic Screening
shutterstock_129794300In a study published in the Journal of Clinical Oncology, researchers found that patients diagnosed with triple-negative breast cancer (TNBC) should be tested for mutations in known predisposition genes, such as BRCA1 and BRCA2. “Clinicians need to think hard about screening all their triple-negative patients for mutations because there is a lot of value in learning that information, both in terms of the risk of recurrence to the individual and the risk to family members. In addition, there may be very specific therapeutic benefits of knowing if you have a mutation in a particular gene,” lead author of the study Fergus Couch, Ph.D., professor of laboratory medicine and pathology at Mayo Clinic said in a news release. TBNC is a difficult malignancy to treat, since these tumors lack estrogen, progesterone and HER-2 receptors, which are the specific targets of many therapeutic drugs. Nonetheless, some studies have found that this type of breast cancer present genetic alterations that render it susceptible to cisplatin, a chemotherapy agent, or PARP inhibitors. In order to assess the mutation frequency in predisposition
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.